Russians at BIO 2012
At the International Convention on Biotechnologies BIO 2012
The Russian delegation was represented by specialists from the Ministry of Industry and Trade and the Ministry of Economic Development of Russia, the State Duma, Russian pharmaceutical companies and pharmaceutical clusters. BIO 2012 was held in 3 groups of events: BIO Business Forum, BIO Exhibition and BIO Educational Program.
The Ministry of Industry and Trade of Russia presented at the BIO International Convention a collective exposition of leading Russian companies developing innovative projects in the field of biotechnology as part of the implementation of the "Strategy for the development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond".
The Russian exposition includes companies leading developments in the biotechnological field – CJSC R-PHARM, LLC International Biotechnological Center Generium, LLC GEROPHARM; as well as LLC OST Rus, which carries out clinical trials; NP Biopharmcluster Severny; state development institutes – JSCRUSNANO, Skolkovo Foundation, RVC OJSC.
At the opening of the Russian exposition, it was announced that R-Pharm CJSC had concluded a licensing agreement with the international pharmaceutical company MSD regarding the rights to the hepatitis C protease inhibitor drug narlaprevir. This agreement was reached during the implementation of the state contract between R-Pharm and the Ministry of Industry and Trade of Russia, concluded within the framework of the Federal Target Program "Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond".
Under the auspices of the Ministry of Industry and Trade of Russia, a broad panel discussion was held within the framework of the Forum: "Innovative transformations of the Russian healthcare sector and the regulatory system. The prospects of the industry beyond the implementation of the Pharma 2020 strategy. The main topic of the discussion was the discussion of new opportunities for international business and investment in Russia, as well as the effective participation of Russian developers in global integration processes and improving the competitiveness of domestic developments.
Deputy Minister of Economic Development of the Russian Federation Oleg Fomichev presented the State Coordination Program for the Development of Biotechnologies in the Russian Federation for the period up to 2020 – "BIO2020" to the court of the world biotechnological community.
At the moment, the documents defining approaches to the global development of biotechnology are an integral part of all the leading economies of the world. They consider the possibilities of reducing dependence on non-renewable energy sources, rational use of natural resources, etc. The strategic goal of the Program is very ambitious: by 2020, it is planned to create a viable and dynamically developing bioeconomy with access to the level of production of biotechnological products in the amount of 1% of GDP by 2020 and 3% of GDP by 2030, which is quite comparable with the leading economies of the world.
At the same time, the main focus is not on the biopharmaceutical industry, which is almost completely covered by the Federal Target Program "Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond", but on industrial, agro- and aquatic technologies, which form the basis of bioeconomics.
During the first year of the Program's implementation, the Russian Government expects more than 30 analytical reports and strategic proposals on various sectors of biotechnology. The program provides for significant changes in legislation and standards governing the industry. Oleg Fomichev stressed that the BIO2020 Program for Russia is actually a base, a platform for building a post-industrial economy, the first stage of transition to a new type of industrialization.
According to him, Russia can and should in a short time become a country with a developed bioeconomy, i.e. an economy based on the rational use of available renewable resources and creating in-demand products with high added value.
The world biotechnological community regarded the approval of the BIO2020 Program as a fundamentally new stage in Russia's economic development and an excellent opportunity for international cooperation in the field of biotechnology.
Portal "Eternal youth" http://vechnayamolodost.ru26.06.2012